Intensive versus conventional glycaemic control for treating diabetic foot ulcers

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Fernando, Malindu E ^a,b   Seneviratne, Ridmee M ^a   Cunningham, Margaret ^a   Lazzarini, Peter A ^c,d   Sangla, Kunwarjit S ^e   Tan, Yong Mong ^e   Buttner, Petra G ^a   Golledge, Jonathan ^a,e  

^a JAMES COOK UNIVERSITY   (Australia)

^b Department of Podiatry   (Australia)

^c QUEENSLAND HEALTH   (Australia)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^e TOWNSVILLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC FOOT; DIABETIC KETOACIDOSIS; DIABETIC RETINOPATHY; DISABILITY-ADJUSTED LIFE YEAR; DISEASE SEVERITY; FEMALE; FOOT AMPUTATION; FOOT ULCER; GANGRENE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HAZARD RATIO; HEALING IMPAIRMENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONKETOTIC DIABETIC COMA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; WOUND HEALING;

EID: 84969980514     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010764     Document Type: Article

References (56)

1. American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care 2012;35(suppl 1):11-63.
2. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008;358(24):2560-72.
3. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot?. Diabetes/Metabolism Research and Reviews 1999;16(Suppl 1):75-83.
4. Armstrong D, Lavery D C, Harkless L. Validation of a diabetic wound classification system - the contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 15th January 1998;21(5):855-9.
5. Bagg W, Whalley GA, Gamble G, Drury PL, Sharpe N, Braatvedt GD. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Internal Medicine Journal 2001;31(6):322-8.
6. Boulton AJM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 2004;47(8):1343-53.
7. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2004;54(6):1615-25.
8. Korzon-Burakowska A, Edmonds M. Role of the microcirculation in diabetic foot ulceration. International Journal of Lower Extremity Wounds 2006;5(3):144-8.
9. Cheung NW, Conn JJ, d'Emden MC, Gunton JE, Jenkins AJ, Ross GP, et al.Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Medical Journal of Australia 2009;191:339-44.
10. Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin A1c predicts healing rate in diabetic wounds. Journal of Investigative Dermatology 2011;131(10):2121-7.
11. Clayton WJr, Elasy TA. A review of the pathophysiology, classification, and treatment of foot ulcers in diabetic patients. Journal of Clinical Diabetes 2009;27(2):52-8.
12. Cook JJ, Simonson DC. Epidemiology and health care cost of diabetic foot problems. In: Veves A editor(s). The Diabetic Foot: Medical and Surgical Management. Boston: Contemporary Diabetes, 2012:17-32.
13. D'Souza DR, Salib MM, Bennett J, Mochin-Peters M, Asrani K, Goldblum SE, et al.Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. Journal of Biological Chemistry 2009;284(27):17947-55.
14. Daroux M, Prévost G, Maillard-Lefebvre H, Gaxatte C, D'Agati VD, Schmidt AM, et al.Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabetes and Metabolism 2010;36:1-10.
15. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabetic Medicine 1997;14(1):29-34.
16. Dinh TL, Veves A. A review of the mechanisms implicated in the pathogenesis of the diabetic foot. International Journal of Lower Extremity Wounds 2005;4(3):154-9.
17. ETG. Type 2 diabetes and cardiovascular disease risk. Australian Electronic Therapeutic Guidelines http://www.tg.org.au/etg_demo/phone/tgc/cvg/951.htm 2012; Vol. Accessed 10th December 2012.
18. Falanga V. Wound healing and its impairment in the diabetic foot. The Lancet 2005;366(9498):1736-43.
19. Game F. Choosing life or limb. Improving survival in the multi-complex diabetic foot patient. Diabetes/Metabolism Research and Reviews 2012;28(Suppl 1):97-100.
20. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Journal of Circulation Research 2010;106(8):1319-31.
21. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circulation Research 2010;107(9):1058-70.
22. Gupta SK, Panda S, Singh SK. The etiopathogenesis of the diabetic foot: an unrelenting epidemic. The International Journal of Lower Extremity Wounds 2010;9(3):127 -31.
23. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al.Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:http://dx.doi.org/10.1136/bmj.d6898.
24. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al.Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD008143.pub2]
25. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
26. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
27. Hinchliffe RJ, Andros G, Apelqvist J, Bakker K, Friederichs S, Lammer J, et al.A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes/Metabolism Research and Reviews 2012;28(Suppl 1):179-217.
28. Hogg FR, Peach G, Price P, Thompson MM, Hinchliffe RJ. Measures of health-related quality of life in diabetes-related foot disease: a systematic review. Diabetologia 2012;55(3):552-65.
29. International Diabetes Federation. IDF diabetes atlas update 2012. The global burden. http://www.idf.org/diabetesatlas/5e/the-global-burden (accessed 10 December 2012).
30. Idris I, Game F, Jeffcoate W. Does close glycaemic control promote healing in diabetic foot ulcers? Report of a feasibility study. Diabetes Medicine 2005;22(8):1060-3.
31. Ikem R, Ikem I, Adebayo O, Soyoye D. An assessment of peripheral vascular disease in patients with diabetic foot ulcer. Foot 2010;20(4):114-7.
32. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al.Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Journal of Diabetes Care 2012;35(6):1364-79.
33. Jeffcoate WJ, Price P, Harding KG, International Working Group on Wound Healing and Treatments for People with Diabetic Foot Ulcers. Wound healing and treatments for people with diabetic foot ulcers. Diabetes/Metabolism Research and Reviews 2004;20(Suppl 1):S78-89.
34. Jones RN, Marshall WP. Does the proximity of an amputation, length of time between foot ulcer development and amputation, or glycemic control at the time of amputation affect the mortality rate of people with diabetes who undergo an amputation?. Advances in Skin & Wound Care 2008;21(3):118-23.
35. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
36. Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD 2009;19(9):596-603.
37. Macisaac RJ, Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Heart, Lung and Circulation 2011;20(10):647-54.
38. Mattila TK, de Boer A. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs 2010;70(17):2229-45.
39. Mazzone T. Intensive glucose lowering and cardiovascular disease prevention in diabetes reconciling the recent clinical trial data. Circulation 2010;122:2201-11.
40. Moher D, Liberati A, Tetzlaff J, Altman DG for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:332-6. [b2535. doi: 10.1136/bmj.b2535]
41. Nathan DM. Understanding the long-term benefits and dangers of intensive therapy of diabetes. Archives of Internal Medicine 2012;172(10):769-70.
42. National Centre for Classification in Health. The Australian Classification of Health Interventions (ACHI) 5th edition- Tabular list of Interventions and alphabetic index of interventions. The University of Sydney, Faculty of Health Sciences 2006.
43. Ogbera OA, Osa E, Edo A, Chukwum E. Common clinical features of diabetic foot ulcers: perspectives from a developing nation. International Journal of Lower Extremity Wounds 2008;7(2):93-8.
44. Rafehi H, El-Osta A, Karagiannis TC. Genetic and epigenetic events in diabetic wound healing. International Wound Journal 2010;8(1):12-21.
45. Robbins JM, Strauss G, Aron D, Long J, Kuba J, Kaplan Y. Mortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration?. Journal of the American Podiatric Medical Association 2008;98:489-93.
46. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes/Metabolism Research and Reviews 2004;20(Suppl 1):S90-5.
47. Schaper NC. Lessons from Eurodiale. Diabetes/Metabolism Research and Reviews 2012;28(Suppl 1):21-6.
48. Shenoy AM. Guidelines in practice: treatment of painful diabetic neuropathy. Continuum Lifelong Learning in Neurology 2012;18(1):192-8.
49. Scottish Intercollegiate Guidelines Network (SIGN) Guidelines. Search filters. http://www.sign.ac.uk/methodology/filters.html#random 2012:accessed (10 December 2012).
50. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005;293(2):217-28.
51. Stegenga ME, van der Crabben SN, Blümer RM, Levi M, Meijers JC, Serlie MJ, et al.Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 2008;112(1):82-9.
52. Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
53. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes/Metabolism Research and Reviews 2012;1(1):8-14.
54. Thomson Reuters. Endnote. http://endnote.com/ 2012; Vol. Accessed 10th July 2013.
55. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.
56. Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient, prevention and treatment. Journal of Vascular Health Risk Management 2007;3(1):65-76.